



Dagmara Hering is a visiting professor at the Medical University of Gdansk, Poland and a Professorial Fellow at Baker IDI Heart and Diabetes Institute, Melbourne, Australia. She is a medical scientist and clinical specialist in internal medicine and hypertension, also recognised by the European Society of Hypertension. Her clinical research has been focused on the role of the sympathetic nervous system and its reflex mechanisms, arterial stiffness, and haemodynamics in the development of hypertension and its progression including cardiovascular and renal complications. She has substantially contributed to the understanding of the efficacy of novel device-based therapies (i.e. slow breathing technique, renal denervation, carotid body denervation) for the management of hypertension, heart failure, and chronic kidney disease. She has received a total of 17 awards including those obtained from the Polish Society of Hypertension, European Society of Hypertension, International Society of Hypertension, High Blood Pressure Research Council of Australia, Polish Academy of Sciences, and Polish Academy of Arts and Sciences. She is a nucleus officer of the European Society of Hypertension Working Group on Hypertension and the Brain, and an expert author contributing to the Lancet Commission on Hypertension, and co-author of over 120 publications including original research papers, review articles, book chapters, and editorials.



Associate Professor **Filip M. Szymański**, MD, PhD is the head of the Cardiovascular Disease Prevention Lab by the First Department of Cardiology, Medical University of Warsaw, Poland and president-elect of Polish Cardiac Society (PCS) Section for Cardiovascular Pharmacotherapy. He is a recipient of the Scientific Award of Club 30 of the PCS, Award of the President of the PCS, Award of the Polish Hypertension Society, several Scientific Awards of the Rector of the Medical University of Warsaw, and two Club 30 grants from the PCS. His projects are focused on novel cardiovascular risk factors in nonclassical, high-risk populations. His research includes thromboembolic risk stratification in atrial fibrillation patients and its association with obstructive sleep apnoea. His discoveries resulted in the description and introduction into clinical practice of a novel clinical entity — OSAFED syndrome.